Advertisement
News
Advertisement

OVA1 Included in Latest ACOG/SGO Committee Opinion

Mon, 03/14/2011 - 6:35am
Bio-Medicine.Org

AUSTIN, Texas, March 14, 2011 /PRNewswire/ -- (Nasdaq: VRML) –Vermillion, a molecular diagnostics company, announced today the inclusion of OVA1® as part of the recently published ACOG/SGO committee opinion. In the March edition of Obstetrics and Gynecology, the American College of Obstetricians and Gynecologists (ACOG) and Society of Gynecologic Oncologists (SGO) published an update committee opinion on the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer.(1) This updates the original opinion, which was published in 2002.  

Significantly, the updated ACOG/SGO opinion cites the FDA clearance of OVA1 and indicates that OVA1 "appears to improve the predictability of ovarian cancer in women with pelvic masses." Although OVA1 is not intended to be a screening test, it "may be useful for evaluating women with a pelvic mass."

Dr. Beth Y. Karlan, M.D. comments, "Using OVA1 to better triage women with a pelvic mass may lead to improvement in outcomes, such as the well-documented improvement in survival among women with cancer who are referred to a gynecologic oncologist for ovarian cancer surgery and treatment, and more streamlined care with possible cost savings if that referral is not necessary."  

Dr. Karlan is Director of the Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center and she holds the Board of Governors Chair in Gynecologic Oncology. Dr. Karlan also is Professor of Obstetrics and Gynecology at the Geffen School of Medicine at the University of California, Los Angeles (UCLA).  She was President of the Society of Gynecologic Oncologists in 2005.

"We are very encouraged by the Committee's recent update," states Gail S. Page, President and CEO of Vermillion, Inc.  "This supports our belief in the utility of OVA1 and the un

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading